1 We have investigated the role of kinin B 1 receptor induction in the endotoxemic rat heart and elucidated the mechanisms underlying B 1 receptor-mediated coronary vasodilation. We also investigated the role of these receptors in endotoxin-induced hypotension. ]-BK (DALBK, 30 nM) signi®cantly (P50.05) inhibited the DABK-induced response (pA 2 =8.4, n=5) whilst HOE140 (B 2 receptor antagonist, 10 nM) was inactive (n=4). 3 Removal of the endothelium or infusion with indomethacin (5 mM), but not L-NAME (300 mM) or ODQ (1 mM), inhibited (485%, P50.05, n=5) the DABK-induced response. DABK caused a dose-dependent release of the prostacyclin metabolite, 6-keto-PGF 1a (E max =0.3 ng ml 71 , n=6). 
Introduction
Kinins act on two receptor types, B 1 and B 2 , classi®ed according to the relative potency of their endogenous agonists (Regoli & Barabe, 1980; Bhoola et al., 1992) . While the B 2 receptor is typically activated by bradykinin (BK) and Lysbradykinin (Lys-BK), the B 1 receptor is selectively sensitive to kinin metabolites without the C-terminal arginine residue, e.g. des-Arg 9 BK (DABK) and Lys-des-Arg 9 BK (Lys-DABK) which show relative selectivity for the rat and human B 1 receptor respectively (Marceau et al., 1998) . B 2 receptors are constitutively expressed and mediate many kinin-dependent in¯ammatory responses including increase in blood¯ow, vascular permeability and accumulation of in¯ammatory cells (Regoli & Barabe, 1980; Bhoola et al., 1992) . B 1 receptors are not expressed in normal physiology but are induced during vascular in¯ammation. Knowledge of the contribution of B 1 receptors to the regulation of vascular tone is of importance since B 1 receptors might replace B 2 receptors during vascular in¯ammation (Marceau et al., 1998) . The selective ligand for B 1 receptors, DABK, normally an inactive metabolite of BK, shows pro-in¯ammatory activity following an in¯ammatory insult in vitro or in vivo (Marceau et al., 1998) . B 1 receptormediated eects are diverse and include vascular smooth muscle contraction, endothelium dependent vasodilation and in¯ammatory cell recruitment (for a recent review see, Marceau et al., 1998) . However, the mechanisms of B 1 receptor induction and function in the heart is unknown.
B 1 receptors may be involved in certain cardiovascular pathologies such as atheromatous disease (Raidoo et al., 1997) and myocardial ischemia (Bouchard et al., 1998) however, of interest to the present study is the possibility that B 1 receptors are induced and play a role in the vascular in¯ammatory response to endotoxin. Kinins are elevated during endotoxemia and experimentally endotoxin treatment is associated with activation of the kallikrein-kinin system (DeLa et al., 1993; Nies et al., 1968) . Since BK is a potent hypotensive agent in humans and animals (Kontos et al., 1964; Regoli & Barabe, 1980) it has been suggested that BK acting at constitutive B 2 receptors contributes to the development of hypotension in sepsis. Reports investigating the eects of B 2 receptor selective antagonists in models of endotoxemia nevertheless are con¯icting showing both bene®cial (Wilson et al., 1989) or no eect (Feletou et al., 1995) . However, administration of a B 2 receptor antagonist with moderate ecacy as a B 1 receptor antagonist (CP-0127) inhibits hypotension and improves survival in rats and rabbits challenged with endotoxin (Whalley et al., 1992) . This compound was also shown to marginally improve survival in patients with gram-negative sepsis (Fein et al., 1997) . It is possible that this marginal bene®cial eect is correlated to the marginal ecacy of this compound at B 1 receptors. Moreover, B 1 receptor de®cient mice display a blunted hypotensive response to endotoxin (Araujo et al., 1998) . It remains unclear however whether the B 1 receptor-mediated hypotensive eect is due to an action at the level of the vasculature or directly on the heart. The eects of endotoxin on the cardiovascular system, both in terms of the systemic vascular action and the direct eects on the heart are at least partially dependent on enhanced NO production but there is a signi®cant NO-independent component (Ungureanu- Longrois et al., 1995; Meng et al., 1997; Filep et al., 1997) . Our hypothesis is that de novo induction of B 1 receptors contributes to the NO-independent regulation of coronary tone and hypotension in endotoxemia. To test this hypothesis we investigated whether endotoxin treatment is associated with cardiac B 1 receptor mRNA expression and correlated this with the development of a coronary vasodilation response ex vivo and a hypotensive response in vivo. We also determined the underlying mechanisms mediating the B 1 receptor induction and coronary vasodilation.
Methods

Animal preparation for in vitro studies
Experiments were performed according to the`Guide on the Operation of Animals (Scienti®c Procedures) Act 1986'. Male Wistar rats (320 ± 370 g Charles River, U.K.) either untreated or treated (1, 2, 3, 6, 14 or 24 h) with lipopolysaccharide (LPS, E. coli 0.55:B5, 2.5 mg kg 71 , i.p.) were heparinized (sodium heparin, 250 iu, i.p.) and killed by cervical dislocation. Hearts were rapidly excised and either frozen in liquid nitrogen for mRNA extraction or placed in ice-cold perfusion solution (constituents below) prior to coronary perfusion pressure (CPP) measurement.
Measurement of coronary hemodynamics
Hearts were cannulated via the aorta and perfused retrogradely under constant¯ow (10 ml min 71 ) using a calibrated roller pump (Gilson, Minipuls-2) with a buer solution of the following composition (mM): D(+)glucose 11.1, CaCl 2 1.4, NaCl 118.5, NaHCO 3 25.0, MgSO 4 1.2, NaH 2 PO 4 1.2 and KCl 4.0; gassed with 95% O 2 /5% CO 2 , (pH 7.4) and perfused at 378C. The CPP in the aortic line was monitored by a Statham Spectramed pressure transducer connected to a chart recorder (Grass 79E). Air temperature was maintained by means of a heated (378C) water jacket. On establishing a stable CPP (20 ± 30 min following cannulation), bolus doses (10 ± 30 ml) of BK, DABK, sodium nitroprusside (SNP) or acetylcholine were administered via the aorta and changes in CPP recorded. Other substances were infused at 0.1 ml min 71 .
Mechanisms of kinin responses
Receptor antagonism studies Control dose-response curves to DABK (10 ± 3000 pmol) or BK (3 ± 1000 pmol) were constructed. Hearts were then perfused with either the B 1 receptor antagonist des-Arg 9 -[Leu 8 ]-bradykinin (DALBK, 30 nM) or the B 2 receptor antagonist HOE140 (0.1 ± 10 nM) for 20 min prior to and during construction of a second dose-response curve. These experiments were repeated in hearts from rats pretreated with LPS (2.5 mg kg
71
; 2, 6, 14 and 24 h). In some experiments CPP was increased in control hearts with endothelin-1 (10 nM, 3 min) prior to the administration of DABK or BK.
Initial studies showed that the induction of the vasodilator response to DABK was maximal in hearts from rats 6 h post LPS-treatment. Therefore the 6 h time point was used in subsequent experiments.
Determination of endothelium-dependency The endothelium was removed by saponin infusion (Ellwood & Curtis, 1997) ; delivered at 20 mg ml 71 in three cycles of 2 min followed by 2 min buer, followed by a 20 min control recovery perfusion. Endothelial and vascular smooth muscle function were tested before and after saponin treatment using the endotheliumdependent vasodilator acetylcholine (3 nmol) and the endothelium-independent vasodilator SNP (10 nmol). DABK (1 nmol)-induced responses were determined before and after saponin.
Involvement of endothelial mediators
In order to investigate involvement of the NO-guanylyl cyclase pathway in mediation of the responses to DABK, dose-response curves were constructed in the absence and presence of either N G -nitro-Larginine methyl ester (L-NAME, 300 mM, 20 min pretreatment) to inhibit NO synthase (NOS) or 1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one (ODQ, 1 mM, 20 min pretreatment) to inhibit soluble guanylyl cyclase (Garthwaite et al., 1995) . The NO-donor SNP was used to verify the activity of ODQ.
To investigate the involvement of prostanoids, doseresponse curves to DABK were constructed in the absence and presence of the cyclooxygenase inhibitor indomethacin (5 mM, 20 min pretreatment). Prostacyclin (PGI 2 ) involvement was assessed by measuring the coronary eux of 6-keto-PGF 1a , the stably hydrolysis product of PGI 2 , released in response to DABK. Fractions (2 min) were collected immediately before and after administration of DABK. Samples were frozen at 7708C until assay of 6-keto-PGF 1a by radioimmunoassay using a commercially available kit (detection limit=0.06 ng ml 71 , Amersham Ltd, Bucks, U.K.).
In vitro B 1 receptor induction
Control hearts were perfused in vitro with either buer solution alone (4 h), LPS (1 mg ml 71 , 4 h) or interleukin-1b (IL-1b, 5 ng ml 71 , 2 h) and the eects of DABK (1 nmol) tested every 15 min. The concentrations of LPS and IL-1b used were based upon circulating concentrations measured during endotoxemia (Waage et al., 1989; Hanasaki et al., 1997) . Responses to BK were also assessed every 30 min during these experiments. At the end of the perfusion hearts were frozen in liquid nitrogen for mRNA extraction. temperature maintained at 378C with a homeothermic blanket. For measurement of mean arterial pressure (MAP) the right common carotid artery was cannulated and connected via a Statham Spectramed pressure transducer to a MacLab4E. The left jugular vein was cannulated for the administration of saline or drugs. To elevate MAP of LPS-treated rats to control levels noradrenaline was infused at a rate of 3 ± 8 mg min 71 .
Reverse-transcription polymerase chain reaction
Poly(A) + mRNA was extracted (Micro-FastTrack kit, Invitrogen, San Diego, CA, U.S.A.) from homogenates of left ventricle, stored at 7708C, from untreated rats, from rats 1,3, or 6 h post LPS treatment in vivo or from hearts perfused in vitro with LPS, IL-1b, or buer solution alone (as described above). Poly(A) + mRNA was resuspended in 20 ml of Tris pH 7.5 and 2 ml aliquots reverse transcribed in a 20 ml-reaction mixture containing 150 ng of random hexanucleotides, 2 mM dNTPs, 50 mM Tris-HCl (pH 8.3), 75 mM KCl, 3 mM MgCl 2 , 10 mM dithiothreitol and 200 U SuperScript II RNAse H 7 reverse transcriptase (Life Technologies, Paisley, U.K.). PCR experiments were performed with 2 ml of the ®rst-strand DNA in a 25 ml reaction mixture containing 200 mM dNTPs, 1.5 mM MgCl 2 , 25 pmol of speci®c forward and reverse primers and 1 U of recombinant Taq DNA polymerase (Life Technologies, Paisley, U.K.) and ampli®ed for 30 cycles (Biometra-TRIO thermocycler): 958C for 1 min, 608C for 2 min and 728C for 2 min followed by a ®nal extension step at 728C for 10 min. Rat B 1 receptor cDNA was ampli®ed with the sense primer (5'-GCGGAAATCTACCTGGCTAACTTG-3') at base position 392 ± 415 and antisense primer (5'-CAGTCACGGGGAG-GAGGAAACC-3') at base position 806 ± 827 of rat B 1 receptor cDNA (Ni et al., 1998) . The quality of RNA samples was evaluated by RT ± PCR using glyceraldehyde-3-phosphate dehydrogenase (GAPDH) speci®c primers (sense primer, 5'-AAGGTGAAGGTCGGAGTCAACG-3' (position 8 ± 29); antisense primer 5'-GGCAGAGATGATGACCCTTTT-GGC-3' (position 362 ± 339). A plasmid containing the mouse B 1 receptor cDNA (Pesquero et al., 1996) was used as the template for the positive PCR control reaction. PCR products were detected by electrophoresis on 2% agarose gels stained with ethidium bromide. The sequence of the ampli®ed cDNA was veri®ed using direct automated DNA sequencing using the TaqDyeDeoxy terminator cycle sequencing method (Thermosequence, Amersham Ltd, U.K.).
Reagents
All reagents were purchased from Sigma Chemical Co. (Dorset, U.K.), unless otherwise indicated below. Lipopolysaccharide (E. coli 055:B5) was purchased from Becton Dickinson (Oxford, U.K.). Des-Arg 10 HOE140 was purchased from RBI (Dorset, U.K.). HOE140 was a kind gift from Hoechst (Frankfurt, Germany) and rat recombinant IL-1b a generous gift from Dr R.C. Newton (Du Pont-Merck, Wilmington, DE, U.S.A.). ODQ was synthesised in The Wolfson Institute for Biomedical Research (London, U.K.).
Data analysis
The responses to DABK and BK are expressed as a percentage of their individual maxima. ED 50 values were calculated from the 50% response level and expressed as geometric mean with 95% con®dence limits in parentheses using a non-linear curve ®tting analysis. The potency of the antagonists was expressed as a pA 2 value. Apparent pA 2 values were calculated using single point analysis from pA 2 =log(DR-1)-log [B] , where DR is the dose-ratio of agonist measured in the absence and presence of antagonist (B). The assumption of simple competition (i.e. slope of unity) between antagonist and agonist was checked with the Schild plot. All other data are given as arithmetic means+s.e.mean or geometric mean with 95% con®dence limits. The number of observations is indicated by n. The signi®cance of dierences between the values was determined by use of Student's paired or unpaired t-test. Dose-response curves were compared using two-way ANOVA (analysis of variance, Graph Pad Prism, Graph Pad Software Inc., San Diego, U.S.A.). The criterion for statistical signi®cance was set at P50.05.
Results
Eects of endotoxin treatment
Treatment of rats with LPS produced characteristic symptoms: pilo-erection, malaise and loose stools. Hearts from LPStreated rats displayed signi®cantly (P50.05) higher basal CPP values than control hearts (CPP (mm Hg)=66+3 (control, n=42); 114+5 (P50.05, 6 h, n=40); 111+14 (14 h, n=4); 94+8 (P50.05, 24 h, n=5).
In¯uence of endotoxin treatment on coronary reactivity to DABK and BK
The B 1 receptor selective agonist DABK had no eect on CPP in hearts from control rats (n=6, Figures 1 and 2) . Elevation of CPP with endothelin-1 (CPP=112.7+15.2, n=4) failed to reveal a response to DABK. In contrast, BK produced dosedependent vasodilations (Figure 1 , ED 50 =37.9 pmol (4.4 ± 329.1); E max =55.4 mm Hg (40.1 ± 70.7), n=13) in control hearts with endothelin-1-elevated CPP. The B 2 receptor antagonist, HOE140 had no eect on basal CPP per se but caused signi®cant rightward shifts (P50.05, 2-way ANOVA) of the dose-response curve to BK in a competitive fashion without aecting the maximum response (pA 2 =10.1+1.5, kg -1 ,6 h) pretreated Schild slope=0.96+0.2, n=13); the B 1 receptor antagonist, DALBK (100 nM) had no signi®cant eect on the doseresponse curve to BK (P40.05, 2-way ANOVA, n=4).
Pretreatment of rats with LPS promoted a time-dependent induction of coronary vasodilation responses to DABK. Whilst DABK had no eect on CPP in hearts taken from rats 2 h post LPS (n=4), marked dose-dependent reductions in CPP were observed after 6 h LPS treatment (ED 50 =149.4 pmol (33.0 ± 675.6); E max =27.0 mm Hg (15.7 ± 36.6), n=9). At the 14 and 24 h time points the E max of the dose-response curves to DABK were signi®cantly reduced (P40.05, two-way ANOVA) relative to the 6 h time point; values were reduced by approximately 50 and 80% respectively (Figure 2) . DALBK (30 nM) had no eect on basal CPP (6 h post-LPS) but caused a signi®cant (P50.05, two-way ANOVA) parallel rightward shift of the dose-response curve to DABK (apparent pA 2 =8.4+0.16, n=5, Figure 3 ) without aecting the maximum response. In contrast HOE140 (10 nM) did not aect either basal CPP or the dose-response curve to DABK (P40.05, two-way ANOVA, n=4, Figure 3 ).
E max values of dose-response curves to BK, in hearts from rats 6 h post LPS (ED 50 =76.0 pmol (27.2 ± 212.2), E max =49.6 mm Hg (39.1 ± 60.0), n=5) appeared to be reduced relative to controls, i.e. control hearts with endothelin-1-elevated CPP, but this eect did not reach statistical signi®cance (P40.05, two-way ANOVA). The BK doseresponse curves in hearts from rats 6 h post LPS were unaltered (P40.05, two-way ANOVA) by DALBK (30 nM) but were signi®cantly inhibited (P50.05, two-way ANOVA) by HOE140 (10 nM) without reducing the maximum response (apparent pA 2 =9.5+0.7, n=5).
Mechanisms of kinin responses
Endothelium removal Endothelium removal produced an increase in CPP in hearts from both untreated rats and rats 6 h post-LPS treatment of 33.7+6.1 mm Hg (n=5) and 23.3+4.2 mm Hg (n=5) respectively (P40.05). Figure 4 shows that removal of the endothelium caused a signi®cant (P50.05) reduction in responses to DABK (1 nmol) and acetylcholine (3 nmol, P50.05) but had no eect on the responses to SNP (10 nmol, P40.05, n=5).
Involvement of endothelial mediators ODQ, whilst producing an increase in CPP of 12.8+3.7 mm Hg (n=5), had no signi®cant eect on the DABK-induced dose-response curves (P40.05, two-way ANOVA, Figure 5 ). ODQ did however completely abolish the dilator response to SNP (10 nmol, n=4, control response=720+4.2 mm Hg; no detectable response following ODQ treatment). L-NAME (n=5) also increased CPP (34.3+4.3 mm Hg) and reduced the response to acetylcholine (3 nmol) by 75+6.2% (n=4), but did not modify the dose-response curve to DABK (P40.05, two-way ANOVA, Figure 5) .
Indomethacin completely abolished the responses to submaximal doses of DABK (51 nmol) and inhibited the maximal response to DABK by 85% (see Figure 5) . Additionally, DABK caused a dose-dependent increase in the concentration of 6-keto-PGF 1a measured in the perfusate (E max =0.3+0.04 ng ml 71 ) of hearts from rats 6 h post-LPS ( Figure 6 ). No increase in 6-keto-PGF 1a levels were observed following DABK administration in hearts from untreated rats (n=3, all doses P50.06 ng ml 71 ).
Mechanisms of B 1 receptor induction
In vitro perfusion of control hearts with LPS (n=6) produced no eect per se on CPP. Perfusion with the in¯ammatory cytokine, IL-1b (n=6) caused a gradual, transient (30 min) reduction in CPP of 33.8+4.0 mm Hg (n=6). Figure 7 shows that both treatments induced a time-dependent induction of a vasodilator response to DABK (1 nmol); the responses peaking at 3 h (IL-1b) and 44 h (LPS). These responses to DABK were completely abolished by indomethacin treatment (n=5) and inhibited by 68.5+7.6% (LPS, n=4) and 67.2+3.9% (IL-1b, n=5) in the presence of DALBK (30 nM). No response to DABK was observed in control hearts perfused for 4 h in the absence of LPS or IL-1b. The initial vasodilator response to BK (0.1 nmol, 54.3+4.4 mm Hg, n=6) was not signi®cantly (P40.05) aected 3 h after the IL-1b perfusion however a 27% reduction was observed after 4 h of LPS treatment (P50.05). The SNP (10 nmol)-induced vasodilation (control response=25+4.9 mm Hg, n=4) was not signi®-cantly aected (P40.05) by either treatment.
Molecular expression of B 1 receptors
RT ± PCR of cardiac mRNA from untreated rats or rats 1 h post-LPS treatment revealed no expression of B 1 receptor mRNA. In contrast, B 1 receptor mRNA was consistently detected in hearts from rats 3 and 6 h post LPS ( Figure 8A) . B 1 receptor mRNA was also detected in hearts perfused in vitro with LPS or IL-1b whereas no expression was detected in non-perfused control hearts ( Figure 8B ). Hearts perfused for 4 h in the absence of LPS or IL-1b also expressed B 1 receptor mRNA. GAPDH mRNA was detected in all hearts tested.
The resulting PCR products derived from two separate samples using B 1 receptor speci®c primers were subjected to automated sequencing. The nucleotide sequence of the ampli®ed cDNA revealed identity with the rat B 1 receptor cDNA sequence (Ni et al., 1998) . Eects of kinins on blood pressure in vivo MAP of control untreated rats was 125.9+2.5 mm Hg (n=8). To compare the activity of DABK in control vs LPS-treated rats MAP in LPS-treated rats was raised using noradrenaline.
MAP of LPS (2.5 mg kg
71
, 6 h)-treated rats infused with noradrenaline was 103.9+3.3 mm Hg (n=10, P40.05 relative to controls). Bolus doses of DABK (1 ± 100 nmol kg 71 ) had no eect on MAP in control untreated rats (n=4) but caused dose-dependent decreases in MAP in LPS (2.5 mg kg 71 , 6 h)-treated rats with an ED 50 of 29.7 (8.3 ± 105) nmol kg 71 and E max of 45.1 (24 ± 66) mm Hg (n=10, Figure 9 ). DALBK (3, 6 nmol kg 71 min 71 , 5 min) signi®cantly (P50.05) reduced the hypotensive eect of DABK (Figure 9 ). DALBK (3 nmol kg 71 min
, 5 min) produced no eect per se in control animals but in LPS (10 mg kg 71 , 6 h)-treated rats it increased MAP by 5. 3+1.2% (n=6, P50.05) 
Discussion
The present study has shown that the kinin B 1 receptor, whilst not basally expressed, is induced by endotoxin in the rat coronary circulation. This was demonstrated both in terms of mRNA expression as detected by RT ± PCR and of a coronary vasodilation response to DABK. Functional responses to DABK increased over time, in parallel with the mRNA expression, peaking at 6 h and almost absent by 24 h postendotoxin treatment. The coronary vasodilation responses to DABK were B 1 receptor-mediated and endothelium-dependent. Furthermore the responses were shown to be mediated by prostanoids but did not involve NO. In vitro treatment with endotoxin revealed that the receptor is induced in the coronary circulation in the absence of circulating cells, possibly by a direct eect of endotoxin within the blood vessel wall.
Induction of B 1 receptor-mediated responses and functional relevance in vivo
A single bolus exposure to endotoxin resulted in the development of a functional response to DABK that was maximal at 6 h and almost absent by 24 h. The loss of response to DABK at 24 h may re¯ect the dierences between a continued in¯ammatory stimulus as opposed to single exposure as in the present study. Whether the functional response is sustained in the presence of a prolonged in¯ammatory stimulus is unclear and warrants further investigation. The B 2 receptor-mediated response to BK was not signi®cantly aected 6 h following endotoxin treatment suggesting that B 2 receptor regulation does not accompany B 1 receptor induction at this time point in this model. However further studies are required to con®rm this. Whilst it is clear that NO plays a major role in the hypotension associated with endotoxemia there is also a signi®cant NO-independent contribution to this response (Ungureanu-Longrois et al., 1995) . Our studies suggest that activation of endotoxin-induced B 1 receptors may have a role to play in mediation of the latter component. Indeed the time course of iNOS induction in endotoxemia in the rat is similar to that found for the B 1 receptor in the present study (Luss et al., 1995; Kinugawa et al., 1997) . This supports our initial hypothesis that the de novo induction of coronary B 1 receptors contributes to an NO-independent regulation of coronary tone and this regulation may have relevance in vivo. Support for the hypothesis that the induction of the B 1 receptor occurred at the level of a speci®c receptor-mediated response was provided by B 1 receptor selective agonist and antagonist studies. The B 1 receptor selective antagonist DALBK (Marceau et al., 1998) inhibited the DABK-induced coronary vasodilations with an apparent pA 2 value of 8.4 and was active against the DABK-induced hypotension in vivo. A partial agonist action of DALBK was also observed both in the isolated heart and on blood pressure which is consistent with its activity at rat B 1 receptors (Marceau et al., 1998) . The B 2 receptor selective antagonist, HOE140, whilst eectively inhibiting the BK-induced coronary vasodilations in both control and endotoxemic hearts did not aect the response to DABK. Whilst these results strongly suggest a speci®c B 1 receptor-mediated response further studies are required to fully con®rm induction at the level of receptor protein.
Basal coronary perfusion pressure was elevated in hearts from endotoxin treated rats compared to controls. It has been suggested that this may be due to release of endothelin-1 (Hohlfeld et al., 1995) . The possibility that elevation of perfusion pressure alone was responsible for the development of responses to DABK was excluded, since raising coronary perfusion pressure with endothelin-1 in control hearts did not reveal a response to DABK whilst responses to BK remained unchanged. This was further demonstrated in hearts from rats 2 h postendotoxin in which coronary perfusion pressure was elevated relative to controls yet no response to DABK was observed.
Mechanisms of B 1 receptor-mediated coronary vasodilation
DABK-induced vasodilation was endothelium-dependent since removal of the endothelium with saponin abolished the response. This loss of response was not due to damage of the smooth muscle since responses to the endothelium-independent vasodilator, SNP, remained unchanged. These results suggest that the induced B 1 receptor expression, in this particular situation, is probably localized to the endothelium. However con®rmation of this will require further studies. These results are in keeping with reports showing endotheliumdependency of induced B 1 receptor-mediated responses in various other blood vessels (Drummond & Cocks, 1995b; including human isolated coronary arteries (Drummond & Cocks, 1995a) .
NO did not play a signi®cant role in mediation of these responses since inhibition of NO synthase had no eect on DABK-induced vasodilation. This is in agreement with the study by Nicolau et al. (1996) who show that the DABKinduced hypotension in endotoxin-treated rats was not aected by NO synthase inhibition. However, it is possible that stimulated NO release from preformed stores could be involved in this response. We found that the guanylyl cyclase inhibitor ODQ, at concentrations shown to inhibit NOmediated eects (this study; Muller et al., 1998) , was also inactive suggesting that the activation of guanylyl cyclase downstream is also not involved. Moreover the observation that the cyclooxygenase inhibitor, indomethacin, abolished the response to DABK suggests that prostanoids, most likely PGI 2 , are the primary if not sole mediator of the response. In support of this, we observed a dose-dependent elevation of 6-keto-PGF 1a levels in the euent following DABK administration. The involvement of endothelial PGI 2 in DABK-induced dilator responses is in agreement with data obtained in other isolated vascular beds; including rabbit mesenteric (Churchill & Ward, 1986) and dog renal (Rhaleb et al., 1989) arteries. However, there are also con¯icting studies excluding prostanoid involvement in DABK-induced vasorelaxation (Pruneau & Belichard, 1993; Pruneau et al., 1996; Santiago et al., 1995; DeWitt et al., 1994) and hypotension (Nicolau et al., 1996) . This dierence may be related to species and regional variation or to the absence of speci®c prostanoid receptor subtypes.
Mechanisms of B 1 receptor induction
In vitro LPS perfusion of normal hearts caused a timedependent induction of functional reactivity to DABK, associated with B 1 receptor mRNA expression, in a similar manner to that achieved with in vivo LPS treatment. These eects appear to be selective for LPS treatment as DABK was inactive in hearts not perfused with LPS. Interestingly, unlike the in vivo situation LPS did not raise CPP in vitro suggesting that this is an in vivo phenomenon. However this requires further investigation. These results suggest that induction of B 1 receptors in the coronary vasculature in vivo is most likely independent of circulating cells and is probably due to a direct eect of LPS on the blood vessel. Indeed experimental neutropenia has no eect on induction of rabbit aortic B 1 receptors by in vivo endotoxin treatment (Bouthillier et al., 1987) .
In¯ammatory cytokines including IL-1b have also been implicated in the pathogenesis of endotoxemia (Bellomo, 1992; Waage et al., 1991; Martich et al., 1993) and are the endogenous trigger for the induction of kinin B 1 receptors in various systems (Marceau et al., 1998) . The present study supports this proposal since following perfusion of hearts with IL-1b vasodilator responses to DABK were observed in parallel with B 1 receptor expression. Since in vitro IL-1b perfusion caused B 1 receptor induction earlier than that achieved by LPS perfusion it is possible that local production of this cytokine, a key mediator in several LPS-induced responses (Glauser, 1996) mediates the in vivo and in vitro eects of LPS, however this requires further investigation for con®rmation. Demonstration of B 1 receptor mRNA expression in control hearts perfused for 4 h, in the absence of added endotoxin, indicates that the experimental process is sucient stimulus to cause spontaneous B 1 receptor induction as found in other in vitro systems Drummond & Cocks, 1995a,b) . However, this modest expression of mRNA was not linked to a functional response to DABK at this time point.
Conclusion
We have shown that endotoxin treatment induces de novo functional B 1 receptor expression in the rat coronary circulation possibly via a direct action within the vessel wall independent of circulating cells. The B 1 receptor-mediated coronary vasodilation is dependent on an intact endothelium and occurs as a result of the secondary release of prostanoids and is independent of NO. The current ®ndings are entirely consistent with the hypothesis that de novo B 1 receptor induction plays a role in the regulation of the coronary circulating during endotoxemia and also suggests that B 1 receptor induction may contribute to the hypotension associated with this pathological condition.
